Clinical Trials Browser

Phase 2 × trilaciclib × Gastrointestinal × Clear all

NCT06569459 2024-08-26

Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer

Phase 2 Recruiting

Gastrointestinal

Esophageal Neoplasms